Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The cytoplasm seems to provide an environment that favors conversion of the prion protein (PrP) to a form with the physical characteristics of the PrP Sc conformation, which is associated with transmissible spongiform encephalopathies. However, it is not clear whether PrP would ever exist in the cytoplasm under normal circumstances. We report that PrP accumulates in the cytoplasm when proteasome activity is compromised. The accumulated PrP seems to have been subjected to the normal proteolytic cleavage events associated with N- and C-terminal processing in the endoplasmic reticulum, suggesting that it arrives in the cytoplasm through retrograde transport. In the cytoplasm, PrP forms aggregates, often in association with Hsc70. With prolonged incubation, these aggregates accumulate in an “aggresome”-like state, surrounding the centrosome. A mutant (D177N), which is associated with a heritable and transmissible form of the spongiform encephalopathies, is less efficiently trafficked to the surface than wild-type PrP and accumulates in the cytoplasm even without proteasome inhibition. These results demonstrate that PrP can accumulate in the cytoplasm and is likely to enter this compartment through normal protein quality-control pathways. Its potential to accumulate in the cytoplasm has implications for pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Aggresomes: A Cellular Response to Misfolded Proteins
Johnston, J. A., Ward, C. L., & Kopito, R. R. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.7.1883 · Cited by 2,148
Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD
Collinge, J., Sidle, K. C. L., Meads, J., Ironside, J., & Hill, A. F. (1996) · Nature · doi:10.1038/383685a0 · Cited by 1,735
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity
Meng, L., Mohan, R., Kwok, B. H. B., Elofsson, M., Sin, N., & Crews, C. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10403 · Cited by 920
A Transmembrane Form of the Prion Protein in Neurodegenerative Disease
Hegde, R. S., Mastrianni, J. A., Scott, M. R., DeFea, K. A., Tremblay, P., Torchia, M., DeArmond, S. J., Prusiner, S. B., & Lingappa, V. R. (1998) · Science · doi:10.1126/science.279.5352.827 · Cited by 729
NMR characterization of the full‐length recombinant murine prion protein, m PrP(23–231)
Riek, R., Hornemann, S., Wider, G., Glockshuber, R., & Wüthrich, K. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00920-4 · Cited by 722
Donne, D. G., Viles, J. H., Groth, D., Mehlhorn, I., James, T. L., Cohen, F. E., Prusiner, S. B., Wright, P. E., & Dyson, H. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13452 · Cited by 674
Protein Glucosylation and Its Role in Protein Folding
Parodi, A. J. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.69 · Cited by 658
UBIQUITIN AND THE CONTROL OF PROTEIN FATE IN THE SECRETORY AND ENDOCYTIC PATHWAYS
Bonifacino, J. S., & Weissman, A. M. (1998) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.14.1.19 · Cited by 613
Characterization and Dynamics of Aggresome Formation by a Cytosolic Gfp-Chimera✪
García-Mata, R., Bebök, Z., Sorscher, E. J., & Sztul, E. S. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.6.1239 · Cited by 595
Cited by
Physiology of the prion protein
Linden, R., Martins, V. R., Prado, M. A. M., Cammarota, M., Izquierdo, I., & Brentani, R. R. (2008) · Physiological Reviews · doi:10.1152/physrev.00007.2007 · Cited by 617
Prions: Protein Aggregation and Infectious Diseases
Aguzzi, A., & Calella, A. M. (2009) · Physiological Reviews · doi:10.1152/physrev.00006.2009 · Cited by 504
Neurotoxicity and Neurodegeneration When PrP Accumulates in the Cytosol
Ma, J., Wollmann, R., & Lindquist, S. (2002) · Science · doi:10.1126/science.1073725 · Cited by 487
Self-citationStress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection
Zanata, S. M. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf325 · Cited by 445
Aggresomes Formed by α-Synuclein and Synphilin-1 Are Cytoprotective
Tanaka, M., Kim, Y. M., Lee, G., Junn, E., Iwatsubo, T., & Mouradian, M. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310994200 · Cited by 422
The two faces of protein misfolding: gain‐ and loss‐of‐function in neurodegenerative diseases
Winklhofer, K. F., Tatzelt, J., & Haass, C. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601930 · Cited by 401
Prions, prionoids and protein misfolding disorders
Scheckel, C., & Aguzzi, A. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0011-4 · Cited by 321
Lewy-body formation is an aggresome-related process: a hypothesis
Olanow, C. W., Perl, D. P., DeMartino, G. N., & McNaught, K. S. P. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00827-0 · Cited by 305
Aggregate formation inhibits proteasomal degradation of polyglutamine proteins
Verhoef, L. G. G. C. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.22.2689 · Cited by 292
Conversion of PrP to a Self-Perpetuating PrP Sc -like Conformation in the Cytosol
Ma, J., & Lindquist, S. (2002) · Science · doi:10.1126/science.1073619 · Cited by 287
Self-citationAggresome‐related biogenesis of Lewy bodies
McNaught, K. S. P., Shashidharan, P., Perl, D. P., Jenner, P., & Olanow, C. W. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02301.x · Cited by 279
Disease-Associated Prion Protein Oligomers Inhibit the 26S Proteasome
Kristiansen, M., Deriziotis, P., Dimcheff, D. E., Jackson, G. S., Ovaa, H., Naumann, H., Clarke, A. R., van Leeuwen, F. W. B., Menéndez-Benito, V., Dantuma, N. P., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.04.001 · Cited by 263
The ubiquitin–proteasome pathway in Parkinson's disease and other neurodegenerative diseases
Ross, C. A., & Pickart, C. M. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.10.006 · Cited by 261
Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson’s disease
McNaught, K. S. P., & Olanow, C. W. (2003) · Annals of Neurology · doi:10.1002/ana.10512 · Cited by 203
Quality Control of Orphaned Proteins
Juszkiewicz, S., & Hegde, R. S. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.001 · Cited by 165
Metadata
- Authors
- Ma, J., & Lindquist, S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2001-12-11
- Volume
- 98
- Issue
- 26
- Pages
- 14955-14960
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2077672823
- Cited by
- 294
- References
- 32
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.